Pastorino U, Valente M, Piva L, Ravasi G
Ann Thorac Surg. 1982 Apr;33(4):320-3. doi: 10.1016/s0003-4975(10)63221-3.
A retrospective evaluation of 199 consecutive patients undergoing resection for lung cancer revealed a significantly shorter long-term survival for those in whom empyema developed postoperatively. The overall five-year survival for the empyema group was 24% compared with 35% in the control group (patients without empyema), and the median survival was 15 months for the control group. These differences in survival were not found among patients with Stage I lung cancer. Pneumonectomy proved to be the main risk factor for the occurrence of empyema after operation, but a minor risk factor was the anatomical extent of disease. this correlation may be explained by major surgical contamination or manipulation as well as by lower immunological host reaction, all related to the extent of the tumor. A lower immunological defense could also explain the worse outcome for patients with Stage II or III lung cancer in whom empyema developed postoperatively.
对199例连续接受肺癌切除术的患者进行回顾性评估发现,术后发生脓胸的患者长期生存率显著缩短。脓胸组的总体五年生存率为24%,而对照组(无脓胸患者)为35%,对照组的中位生存期为15个月。在I期肺癌患者中未发现这些生存差异。肺切除术被证明是术后发生脓胸的主要危险因素,但次要危险因素是疾病的解剖范围。这种相关性可能是由于主要的手术污染或操作以及较低的宿主免疫反应,所有这些都与肿瘤范围有关。较低的免疫防御也可以解释II期或III期肺癌患者术后发生脓胸时预后较差的原因。